论文部分内容阅读
目的研究更昔洛韦在预防和治疗肝移植术后巨细胞病毒(CMV)感染和CMV性肺炎中的作用和疗效。方法回顾性分析2003年10月至2005年9月完成的480例肝移植患者的临床资料,总结分析更昔洛韦在预防和治疗肝移植术后CMV感染和CMV性肺炎中的临床效果。结果肝移植术后有402例患者使用国产更草洛韦(丽科伟)预防CMV感染,其中53例术后发生CMV感染;47例患者使用进口更昔洛韦预防CMV感染.其中6例术后发生CMV感染。480肝移植患者术后有6例确诊为CMV性肺炎,使用国产更昔洛韦治疗4例,用进口更昔洛韦治疗2例;经治疗后,5例痊愈,1例出现呼吸功能衰竭死亡。结论更昔洛韦可以有效预防肝移植术后CMV感染;使用以更昔洛韦为主要抗病毒药物的综合治疗对CMV肺炎有较好疗效。
Objective To study the effect and effect of ganciclovir in the prevention and treatment of cytomegalovirus (CMV) infection and CMV pneumonia after liver transplantation. Methods The clinical data of 480 liver transplant patients completed from October 2003 to September 2005 were retrospectively analyzed. The clinical effect of ganciclovir in the prevention and treatment of CMV infection and CMV pneumonia after liver transplantation was analyzed. Results After liver transplantation, 402 patients were treated with domestic grass carvedilol (DLK) to prevent CMV infection, of which 53 patients were infected with CMV postoperatively and 47 patients were treated with imported ganciclovir to prevent CMV infection, of which 6 patients After the occurrence of CMV infection. 480 patients with liver transplantation were diagnosed as CMV pneumonia in 6 cases, 4 cases with domestic ganciclovir and 2 cases with imported ganciclovir. After treatment, 5 cases recovered and 1 case died of respiratory failure . Conclusion Ganciclovir can effectively prevent CMV infection after liver transplantation. The combination therapy with ganciclovir as the main antiviral drug has good curative effect on CMV pneumonia.